Cannabis Companies: Companies and Non-Psychoactive Ingredient

cannabis companies: The FDA in December provided guidelines that say companies cannot move to market without its approval, but Gottlieb said he could envisage a model that would leave high concentrations of CBD to pharmaceutical companies and potentially allow smaller concentrations in food or dietary supplements, according to Market Watch. Rob DiPisa, co-chair of the Cannabis Law Group at law firm Cole Schotz, said that scenario makes sense. Many cannabis companies are planning to launch food, drink and cosmetics lines that contain CBD, a non-psychoactive ingredient in cannabis that is widely believed to have wellness properties, but which has not been subjected to the kind of research that has been conducted on THC, the plant's psychoactive ingredient. The FDA can't force pharma companies to go through a long process with clinical research and trials and then let someone at the gym just put CBD into a smoothie, he said. That's an incentive for them to invest in R&D. For all of Market Watch's coverage of cannabis companies, click here. So, it's good he hinted at only allowing low levels in food and drink and reserving higher levels for pharma products. (news.financializer.com). As reported in the news.